
Josh Long
Reporter at Informa
Legal and Regulatory Editor at SupplySide Supplement Journal
Journalist, lawyer by training, slow hockey player, cheese curds addict
Articles
-
1 month ago |
perkinscoie.com | Josh Long
Dietary supplement companies faced 58 new class action lawsuits in 2024, roughly on par with the previous year (62) although far below a record high in 2022, according to an annual report published by the law firm Perkins Coie. Over the last three years, the supplement sector has been targeted with 225 new class action lawsuits, based on Perkins Coie data.
-
2 months ago |
newhope.com | Josh Long
Staff cuts in the FDA's Office of Dietary Supplement Programs have prompted concerns about product safety among some industry leaders. Read on for their analyses. Josh Long, Associate editorial director, SupplySide Supplement JournalAt a GlanceThe staff reduction at the FDA is part of the Trump Administration's plan to reduce waste and cut the federal budget. About 700 employees at the FDA have lost their jobs, according to The New York Times.
-
Jan 24, 2025 |
blogs.vmware.com | Josh Long
Hi, Spring fans! Welcome to another installment of This Month in Spring! It’s the first This Month in Spring of the new year! And we’ve got a ton of good stuff to look at, no doubt, but this installment is also an ample opportunity in which to look at the year that was.. 2024! (we knew ye when…)I write this edition from a desk overlooking the beautiful island of St. Barths, a beautiful island nation in the French Caribbean.
-
Jan 17, 2025 |
newhope.com | Josh Long
A lawsuit against the government and amended citizen petition filed with the U.S. Food and Drug Administration by the Natural Products Association could determine the future of β-NMN in dietary supplements, with potentially larger implications for innovation in a $67 billion-a-year industry. Josh Long, Associate editorial director, SupplySide Supplement JournalAt a GlanceThe FDA’s interpretation of the drug exclusion clause will affect NMN supplements and other natural ingredients.
-
Jan 15, 2025 |
supplysidefbj.com | Josh Long
The decision comes after a petition showed the additive induces cancer in male rats, but FDA said the same risks aren’t applicable to humans. Josh Long, Associate editorial director, SupplySide Supplement JournalAt a GlanceFDA is revoking the authorized uses of Red 3 in food and ingested drugs. A CSPI petition called Red 3 a “carcinogen” and urged FDA to “take immediate action to prohibit” its use. FDA nonetheless faces criticism over waiting so long to ban the dye.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 9
- Tweets
- 3
- DMs Open
- No